This Is My No. 1 Recommended Vanguard ETF to Buy in 2026

Vanguard’s Health Care ETF (VHT), which tracks a benchmark of more than 400 healthcare stocks, has outperformed the S&P 500 over the past six months after lagging on a five‑year basis and is up roughly 2% year-to-date in 2026. The sector’s rebound is underpinned by strong adoption of GLP‑1 weight‑loss drugs, led by Eli Lilly (VHT’s largest holding), with Morgan Stanley forecasting the obesity‑drug market could expand to $150 billion by 2035 from $15 billion in 2024. For managers seeking defensive diversification away from tech-heavy exposures, VHT — offered within Vanguard’s low‑cost ETF lineup alongside VOO/VTI — presents thematic exposure to both defensive demand and drug-driven growth opportunities.

Analysis

Market structure: Short-term winners are large-cap healthcare names (Eli Lilly/LLY, JNJ, PFE-sized holdings inside VHT) and ETFs like VHT as allocators rotate into defensive, cash-generative sectors; cyclical consumer and high-multiple tech (QQQ, NVDA) are the natural losers if flows reallocate 2–5% of equity AUM into health. GLP‑1 adoption (MS estimate from $15bn to $150bn by 2035) boosts pricing power for market leaders, concentrating revenue upside into a handful of large-cap pharma and biotech and tightening supply chains for APIs and manufacturing capacity. Cross-asset: an outsized rotation into defensives typically compresses equity risk premia and can modestly lower 2s–10s yields by 10–30bps while lifting IG credit spreads tighter for healthcare issuers.

Risk assessment: Key tail risks are regulatory/pricing intervention (Medicare formulary, US pricing reform) and patent/antitrust litigation that could cut peak GLP‑1 assumptions by >30% within 12–24 months. Immediate (days) risk: momentum reversal and fund-flow churn; short-term (weeks–months): earnings or FDA setbacks; long-term (years): market-share shifts as new entrants scale. Hidden dependencies include VHT’s concentration in a few mega-cap stocks (single-stock moves can swing ETF by >5%) and payer reimbursement negotiations that can materially change realized pricing.

Trade implications: Direct: establish 2–3% portfolio long in VHT (6–12 month horizon) and a 1–2% concentrated long in LLY via a 6–9 month call spread (limit max spend to 1% notional) to capture GLP‑1 growth while capping downside. Pair trade: overweight VHT +2% vs underweight QQQ −2% (target outperformance 150–300bps over 3–9 months). Options: buy a 3‑month SPY 2% OTM put as a portfolio tail hedge sized to cap drawdown at ~3% of NAV.

Contrarian angles: The consensus neglects regulatory/regional reimbursement risk and the fact recent 6‑month outperformance (VHT +2% YTD) may be momentum-driven — not fundamentals-based; this makes small-cap biotech a potential source of alpha if you can pick winners but also a volatility trap. Historical parallel: 2014–2016 drug booms saw heavy winners early then sharp regulatory repricing; if GLP‑1 pricing or supply becomes contested, expect a 20–40% reset in high‑multiple names, creating entry points.

Key Decisions for Investors

• Establish a 2–3% portfolio long in Vanguard Health Care ETF (VHT) with a 6–12 month horizon; take profits if VHT outperforms the S&P by +15–20% or cut to breakeven on a VHT decline of -10%.
• Add a 1–2% directional position in Eli Lilly (LLY) via a 6–9 month debit call spread (size cost ≤1% of NAV) to capture GLP‑1 upside; close on a 30% trade profit or on any material regulatory announcement (CMS/FDA) within 0–90 days.
• Implement a pair trade: overweight VHT by +2% and underweight QQQ by -2% (or short equivalent notional) targeting 150–300bps relative outperformance over 3–9 months; exit if spread reverses by >100bps in 30 days.
• Purchase a 3‑month SPY 2% OTM put sized to limit portfolio drawdown to ~3% of NAV as insurance; review and roll if VIX rises above 22 or if MACRO CPI surprises >+0.3% MoM.